Trial Profile
A Phase IIa proof of concept study of ADX71149 in Epilepsy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs ADX 71149 (Primary) ; Levetiracetam (Primary)
- Indications Epilepsy
- Focus Proof of concept; Therapeutic Use
- 06 Feb 2023 Status changed from planning to recruiting.
- 06 Feb 2023 According to Addex Therapeutics media release, based on the outcome of this review and recommendations from the IRC, Janssen will evaluate the next steps for the program around the quarter end of 2023.
- 06 Feb 2023 According to Addex Therapeutics media release, data from part I will be evaluated by an independent interm review committee (IRC) to ensure the study remains blinded.